SpectRx
This article was originally published in The Gray Sheet
Executive Summary
Diabetes management firm sells BiliChek noninvasive bilirubin analyzer product line to sleep apnea firm Respironics for use in monitoring infant jaundice. Respironics will pay a base purchase price of $4 mil., another $1 mil. after the completion of product development, and an additional $6.25 mil. over five years in royalties and earn out payments based on realized revenues. BiliChek predicts the level of bilirubin, which causes infant jaundice, by assessing the amount of light reflected off the forehead and will be an alternative to taking blood from the heel and waiting for lab results. SpectRx is divesting the product to focus on development of a continuous glucose monitor...